middle.news
Imugene’s Azer-cel Hits 82% Response Rate, FDA Clears Path for Pivotal Trial
9:40am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
Imugene’s Azer-cel Hits 82% Response Rate, FDA Clears Path for Pivotal Trial
9:40am on Friday 30th of January, 2026 AEDT
Key Points
82% overall response rate in relapsed/refractory DLBCL patients
83% response rate in CAR T naïve lymphoma cohort
FDA endorses azer-cel’s development strategy and trial design
New collaboration with JW Therapeutics to advance onCARlytics program
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMUGENE (ASX:IMU)
OPEN ARTICLE